Advanced BioScience Laboratories announced it has been awarded a contract for "Preclinical and translational vaccine development for HIV and other candidate agents" by the Division of AIDS (DAIDS) within the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH).
According to the WHO, there are over 38 million individuals living with HIV worldwide. The development of a safe and efficacious HIV-1 vaccine remains one of the highest priorities of the NIAID. The purpose of this contract is to support the full range of activities for preclinical and translational support services from initial product discovery through full (CGMP) manufacturing and readiness for clinical trials and/or product licensure.
ABL & NIAID Partnership
The seven-year contract has a total potential funding value of $364.5 million. ABL will provide DAIDS with preclinical and translational development of promising vaccines and related products for HIV and other candidate agents. ABL will provide its portfolio of services that includes feasibility studies, process and assay development, cGMP production, safety and efficacy studies, and product release and stability testing.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!